Montanova Capital LLC Purchases 274,184 Shares of Capricor Therapeutics, Inc. $CAPR

Montanova Capital LLC grew its holdings in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 7.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,092,784 shares of the biotechnology company’s stock after buying an additional 274,184 shares during the period. Capricor Therapeutics accounts for 1.6% of Montanova Capital LLC’s portfolio, making the stock its 19th biggest position. Montanova Capital LLC owned approximately 7.04% of Capricor Therapeutics worth $98,554,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Royal Bank of Canada raised its holdings in Capricor Therapeutics by 12.4% in the 4th quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares in the last quarter. KBC Group NV bought a new position in Capricor Therapeutics in the first quarter worth about $44,000. ACT Capital Management LLC purchased a new stake in Capricor Therapeutics in the fourth quarter worth about $43,000. Nuveen LLC raised its position in shares of Capricor Therapeutics by 2.1% in the 4th quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after acquiring an additional 1,878 shares in the last quarter. Finally, State of Wyoming boosted its position in shares of Capricor Therapeutics by 76.0% during the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock valued at $128,000 after purchasing an additional 1,913 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Price Performance

Shares of CAPR opened at $9.91 on Tuesday. The business has a fifty day moving average of $14.07 and a 200 day moving average of $24.19. The firm has a market capitalization of $576.17 million, a P/E ratio of -4.04 and a beta of 0.54. Capricor Therapeutics, Inc. has a one year low of $2.96 and a one year high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.11). Analysts expect that Capricor Therapeutics, Inc. will post -1.72 EPS for the current fiscal year.

Key Capricor Therapeutics News

Here are the key news stories impacting Capricor Therapeutics this week:

• Positive Sentiment: The FDA has extended its review of Capricor’s Biologics License Application for deramiocel, meaning the application remains under regulatory consideration. Hagens Berman FDA review extension alert
• Neutral Sentiment: Multiple law firms reiterated that investors who purchased CAPR securities from December 17, 2025, through July 26, 2026, have until September 28, 2026, to seek appointment as lead plaintiff in the pending class action. These announcements repeat the same deadline and do not represent new court findings or a determination of liability. Robbins Geller Capricor investor deadline notice
• Negative Sentiment: The securities lawsuit alleges that Capricor misled investors about the progress of deramiocel’s application toward the August 22, 2026 PDUFA date by allegedly failing to disclose that the final statistical analysis plan for the HOPE-3 study had not been submitted to or agreed upon by the FDA before the application was resubmitted. The allegations and related regulatory scrutiny create legal, reputational, and approval risks for CAPR. Levi and Korsinsky Capricor shareholder alert
• Negative Sentiment: A series of investor-law-firm announcements highlighted the pending fraud case and referenced a prior sharp selloff following clinical-data and regulatory disclosures. The repetition of these notices keeps the litigation overhang prominent and may weigh on sentiment even as the FDA review continues. BFA Law Capricor investment losses alert

Analyst Upgrades and Downgrades

CAPR has been the subject of several recent research reports. JonesTrading lowered Capricor Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, July 31st. Wall Street Zen lowered shares of Capricor Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Alliance Global Partners lowered shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 target price for the company. in a report on Tuesday, July 28th. HC Wainwright reiterated a “neutral” rating on shares of Capricor Therapeutics in a research note on Monday, July 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Hold” and a consensus target price of $29.15.

Insider Activity

In other news, CFO Anthony Bergmann sold 24,100 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer directly owned 11,223 shares in the company, valued at $340,954.74. This represents a 68.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last ninety days, insiders have sold 25,000 shares of company stock worth $759,158. Insiders own 9.20% of the company’s stock.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.